Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pasithea Therapeutics (KTTA) Cash from Operations (2021 - 2024)

Pasithea Therapeutics (KTTA) has disclosed Cash from Operations for 4 consecutive years, with 2443036.0 as the latest value for Q4 2024.

  • Quarterly Cash from Operations rose 25.84% to 2443036.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was 13923438.0 through Dec 2024, down 8.66% year-over-year, with the annual reading at 15211490.0 for FY2025, 9.25% down from the prior year.
  • Cash from Operations hit 2443036.0 in Q4 2024 for Pasithea Therapeutics, up from 3120451.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 381845.0 in Q1 2021 to a low of 4621594.0 in Q3 2022.
  • Historically, Cash from Operations has averaged 2612887.25 across 4 years, with a median of 3100058.5 in 2023.
  • Biggest five-year swings in Cash from Operations: plummeted 742.68% in 2022 and later grew 29.94% in 2023.
  • Year by year, Cash from Operations stood at 1744333.0 in 2021, then plummeted by 82.61% to 3185388.0 in 2022, then decreased by 3.42% to 3294344.0 in 2023, then rose by 25.84% to 2443036.0 in 2024.
  • Business Quant data shows Cash from Operations for KTTA at 2443036.0 in Q4 2024, 3120451.0 in Q3 2024, and 4038866.0 in Q2 2024.